Hi, Shveta, congratulations on a great quarter and the year. So my first question is on if I see the business over the last few quarters, so we are seeing incremental growth coming from data centers, both from Colo and Hyperscalers. And also after the transiti on of CPCB IV+, we have seen after treatment products gaining momentum. So, my question is, as we move to services on the distribution side of CPCB IV+ engines and also on the data center has the potential of scaling up, our related party transactions are significantly lower because we are sourcing this from CTIPL or to imports. So in light of this, how do you think about localization? How do you think about margins? Because higher growth comes from these segments, it could be potentially margin dilutive to the overall company. So that's my first question.
In particular, I was talking about QSK60, which is done by CTIPL and then QSK95 which we import. So as of now, if you can give some color on the percentage of revenue, how both of these could have contributed. And since we are expecting these to come in da ta centers over the next 3, 4 years, and the data center contributes 25% to the PowerGen overall revenues, and if it grows faster than the non-data center business, so don't you think over the next 3 to 4 years, this could actually start diluting it? Maybe right now not meaningful contribution to revenues, but then if it increases, then it will start hurting us?